WallStreetZenWallStreetZen

NASDAQ: VRAX
Virax Biolabs Group Ltd Earnings & Revenue

OverviewForecastEarnings
DividendOwnership

VRAX past revenue growth

How has VRAX's revenue growth performed historically?
Company
1,276.75%
Industry
151.46%
Market
17.61%
VRAX's revenue has grown slower... subscribe to Premium to read more.
Revenue Growth vs Industry Performance
VRAX's revenue has grown slower... subscribe to Premium to read more.
Revenue Growth vs Market Performance
VRAX's revenue growth is accelerating... subscribe to Premium to read more.
Accelerating Revenue Growth Performance

VRAX earnings and revenue history

Current Revenue
$79.3k
Current Earnings
-$6.9M
Current Profit Margin
-8,730.7%

VRAX Return on Equity

Current Company
-129.1%
Current Industry
15.4%
Current Market
-9.4%
VRAX's Return on Equity (-129.1%)... subscribe to Premium to read more.
High Return on Equity Performance

Be the first to know when VRAX announces earnings.

VRAX Return on Assets

Current Company
-112.4%
Current Industry
2.2%
VRAX is generating lower Return... subscribe to Premium to read more.
Above Average Return on Assets Performance

VRAX Return on Capital Employed

Current Company
-110.73%
Current Industry
17.7%

VRAX vs Biotech Stocks

TickerRevenueEBITDAEarningsY/Y RevenueY/Y Earnings
VRAX$79.30kN/A-$6.92M-15.02%N/A
SPRC$797.51k$1.87M$1.42M+108.44%N/A
ATNF$0.00-$22.13M-$19.94MN/AN/A
NBSE$0.00-$12.55M-$13.73MN/AN/A
GRI$0.00-$10.95M-$13.04M-100.00%N/A
View Top Biotech Stocks

Virax Biolabs Group Earnings & Revenue FAQ

What were VRAX's earnings last quarter?

Virax Biolabs Group (NASDAQ: VRAX) reported Q3 2023 earnings per share (EPS) of N/A, up N/A year over year. Total Virax Biolabs Group earnings for the quarter were N/A. In the same quarter last year, Virax Biolabs Group's earnings per share (EPS) was N/A.

If you're new to stock investing, here's how to buy Virax Biolabs Group stock.

What was VRAX's earnings growth in the past year?

As of Q2 2024, Virax Biolabs Group's earnings has grown year over year. Virax Biolabs Group's earnings in the past year totalled -$6.92 million.

What was VRAX's revenue last quarter?

Virax Biolabs Group (NASDAQ: VRAX) reported Q3 2023 revenue of N/A up N/A year over year. In the same quarter last year, Virax Biolabs Group's revenue was N/A.

What was VRAX's revenue growth in the past year?

As of Q2 2024, Virax Biolabs Group's revenue has grown 1,276.75% year over year. This is 1,125.3 percentage points higher than the US Biotechnology industry revenue growth rate of 151.46%. Virax Biolabs Group's revenue in the past year totalled $79.30 thousand.
©2024 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.